Диссертация (1154682), страница 18
Текст из файла (страница 18)
– 2016. – vol. 17(1). – p. 54–60.122-Marso S.P., Miller T., Rutherford B.D., Gibbons R.J., Qureshi M.,Kalynych A., Turco M., Schultheiss H.P., Mehran R., Krucoff M.W., LanskyA.J., Stone GW. Comparison of myocardial reperfusion in patients undergoingpercutaneous coronary intervention in ST-segment elevation acute myocardialinfarction with versus without diabetes mellitus (from the EMERALD Trial). //Am J Cardiol. –2007. – vol.
100(2). – p. 206–210.124123-Matheeussen V., Jungraithmayr W., De Meester I. Dipeptidyl peptidase 4as a therapeutic target in ischemia/reperfusion injury. // Pharmacol Ther. – 2012.– vol. 136(3). – p. 267 – 282.124-Matsubara J., Sugiyama S., Akiyama E., Iwashita S., Kurokawa H., OhbaK., et al. Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelialdysfunction in association with its anti-inflammatory effects in patients withcoronaryarterydiseaseanduncontrolleddiabetes.//Circ J. – 2013.
– vol. 77(5). – p. 1337 – 1344.125-Matsushita K., Blecker S., Pazin-Filho A., Bertoni A., Chang P.P., CoreshJ. et al. The association of hemoglobin A1c with incident heart failure amongpeople without diabetes: The atherosclerosis risk in communities study. //Diabetes. –2010. –vol. 59(8). – p.
2020 – 2026.126-Mayer L,. Levine В., Kalman J. et al. // New. Engl. J. Med. –1990. – vol.323(4). – p. 236-241.127-McGavock J.M., Lingvay I., Zib I., Tillery T., Salas N., Unger R., LevineB.D., Raskin P., Victor R.G., Szczepaniak L.S. Cardiac steatosis in diabetesmellitus: a 1H-magnetic resonance spectroscopy study. // Circulation. – 2007.
–Vol. 116(10). – p. 1170–1175128-Miki T., Yuda S., Kouzu H., Miura T. Diabetic cardiomyopathy:Pathophysiology and clinical features. // Heart Fail Rev. – 2013. – vol .18(2). –p. 149 – 166.129-MondilloS., GalderisiM., Mele D. etal. Speckle-trackingechocardiography: a new technique for assessing myocardial function. // JUltrasound Med. – 2011.
– vol. 30 (1). – p. 71-83.130-Monji A., Mitsui T., Bando Y.K., Aoyama M., Shigeta T., Murohara T.Glucagon-like peptide-1 receptor activation reverses cardiac remodeling vianormalizing cardiac steatosis and oxidative stress in type 2 diabetes. // Am JPhysiol Heart Circ Physiol. – 2013. – vol. 305(3). – p. H295 – H304.125131-Muranaka A., Yuda S., Tsuchihashi K., Hashimoto A., Nakata T., MiuraT., Tsuzuki M., Wakabayashi C., Watanabe N., Shimamoto K. Quantitativeassessment of left ventricular and left atrial functions by strain rate imaging indiabetic patients with and without hypertension.
// Echocardiography. –2009. –vol. 26. – p. 262–271.132-Murohara T. Dipeptidyl peptidase-4 inhibitor: Another player forcardiovascular protection. // J Am Coll Cardiol. –2012. – vol. 59. – p. 277 – 279.133-Neely JR, Rovetto M.J., Oram J.F. Myocardial utilization of carbohydrateand lipids. // Prog Cardiovasc Dis. –1972. –vol.
15(3). – p. 289 – 329.134-Ng AC., Delgado V., Bertini M., van der Meer RW., Rijzewijk L.J.,Shanks M., Nucifora G., Smit J.W., Diamant M., Romijn J.A., de Roos A.,Leung D.Y., Lamb H.J., Bax J.J. Findings from left ventricular strain and strainrate imaging in asymptomatic patients with type 2 diabetes mellitus. // Am JCardiol. –2009.
–vol.104. – p. 1398–1401.135-Ng AC., Delgado V., Bertini M., van der Meer R.W., Rijzewijk L.J., HooiEwe S., Siebelink H.M., Smit J.W., Diamant M., Romijn J.A., de Roos A.,Leung D.Y., Lamb H.J., Bax J.J.. Myocardial steatosis and biventricular strainand strain rate imaging in patients with type 2 diabetes mellitus.
// Circulation.–2010. –Vol.122. – p. 2538–2544.136-Noyan-Ashraf M.H., Shikatani E.A., Schuiki I., Mukovozov I., Wu J., LiR.K. et al. A glucagon-like peptide-1 analog reverses the molecular pathologyand cardiac dysfunction of a mouse model of obesity. // Circulation. –2013. –vol. 127(1). – p. 74 – 85.137-Ogawa H., Nakayama M., Morimoto T., Uemura S., Kanauchi M., Doi N.et al. Low-dose aspirin for primary prevention of atherosclerotic events inpatients with type 2 diabetes: A randomized controlled trial. // JAMA. –2008. –vol. 300(18). – p. 2134 – 2141.138-Orem C., Kucukosmanoglu M., Hacihasanoglu A., Yilmaz R., Kasap H.,Erdogan T.
et al. Association of Doppler-derived myocardial performance index126with albuminuria in patients with diabetes. // J Am Soc Echocardiogr. –2004. –vol. 17(11). – p. 1185–90.View ArticlePubMed139-Parra V., Verdejo H.E., Iglewski M., Campo A.D., Troncoso R., Jones D.,et al. Insulin stimulates mitochondrial fusion and function in cardiomyocytes viathe Akt-mTOR-NFkappaB-Opa-1 signaling pathway. // Diabetes.
–2014. –vol.63(1). – p. 75 – 88.140-Paulus W.J., Tschope C. A novel paradigm for heart failure with preservedejection fraction: Comorbidities drive myocardial dysfunction and remodelingthrough coronary microvascular endothelial inflammation. // J Am Coll Cardiol.–2013. –vol. 62(4). – p. 263 – 271.141-Pe ´rez J.E., McGill J.B., Santiago J.V., Schechtman K.B., WaggonerA.D., Miller J.G., Sobel B.E. Abnormal myocardial acoustic properties indiabetic patients and their correlation with the severity of disease. // J Am CollCardiol.
–1992. –vol.19. – p. 1154–1162.142-Per-Henrik Groop., Merlin C. Thomas., John L. Moran., et al. ThePresence and Severity of Chronic Kidney Disease Predicts All-Cause Mortality inType 1 diabetes. // Diabetes. –2009. –vol. 58(7). – p. 1651–1658.143-Petter Bjornstad., David M. Maahs., Lindsey M.
Duca. Estimated insulinsensitivity predicts incident micro- and macrovascular complications in adultswith type 1 diabetes over 6 years: the coronary artery calcification in type 1diabetes study.// Journal of Diabetes and Its Complications. –2016. –vol. 30(4).– p.
586-590.144-Picano E., Pelosi G., Marzilli M., Lattanzi F., Benassi A., Landini L.,L’Abbate A. In vivo quantitative ultrasonic evaluation of myocardial fibrosis inhumans. // Circulation. –1990. –vol. 81(1). – p. 58–64.145-Poirier P., Bogaty P., Garneau C., Marois L., Dumesnil J.G. Diastolicdysfunction in normotensive men with well-controlled type 2 diabetes:importance of maneuvers in echocardiographic screening for preclinical diabetic127cardiomyopathy. // Diabetes Care. –2001. –vol.24(1). – p. 5–10.ViewArticlePubMed.146-Poornima I.G., Parikh P., Shannon R.P.
Diabetic cardiomyopathy: Thesearch for a unifying hypothesis. // Circ Res. –2006. –vol. 98(5). – p. 596 – 605.147-Proost P., Struyf S., Schols D., Opdenakker G., Sozzani S., Allavena P.,et al. Truncation of macrophage-derived chemokine by CD26/dipeptidylpeptidase IV beyond its predicted cleavage site affects chemotactic activity andCC chemokine receptor 4 interaction. // J Biol Chem. –1999. –vol. 274(7).
– p.3988 – 3993.148-Ramirez .E, Klett-Mingo M., Ares-Carrasco S., Picatoste B., Ferrarini A.,Ruperez F.J., et al. Eplerenone attenuated cardiac steatosis, apoptosis anddiastolic dysfunction in experimental type-II diabetes. // Cardiovasc Diabetol. –2013. –vol.12. – p. 172.149-Rijzewijk L.J., van der Meer R.W., Smit J.W., Diamant M., Bax J.J.,Hammer S., et al.
Myocardial steatosis is an independent predictor of diastolicdysfunction in type 2 diabetes mellitus. // J Am Coll Cardiol. –2008. –vol.52(22). – p. 1793 – 1799.150-Roberto M. Lang., Luigi P. Badano., Victor Mor-Avi., Jonathan Afilalo.,Anderson Armstrong. Recommendations for Cardiac Chamber Quantificationby Echocardiography in Adults: An Update from the American Society ofEchocardiography and the European Association of Cardiovascular Imaging.
//J Am Soc Echocardiogr. –2015. –vol.28. – p. 1-39.151-Rubin J., Matsushita K., Ballantyne CM., Hoogeveen R., Coresh J., SelvinE. Chronic hyperglycemia and subclinical myocardial injury. // J Am CollCardiol. –2012. –vol. 59(5). – p. 484 – 489.152-Rubler S., Dlugash J., Yuceoglu Y.Z., Kumral T., Branwood A.W.,Grishman A. New type of cardiomyopathy associated with diabeticglomerulosclerosis.
// Am J Cardiol. –1972. –vol. 30(6). – p. 595–602.128153-Ryden L., Grant P.J., Anker S.D., Berne C., Cosentino F., Danchin N., etal. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseasesdeveloped in collaboration with the EASD: The Task Force on diabetes, prediabetes, and cardiovascular diseases of the European Society of Cardiology(ESC) and developed in collaboration with the European Association for theStudy of Diabetes (EASD).
// Eur Heart J. –2013. –vol. 34(39). – p. 3035 – 3087.154-Sacre J.W., Franjic B., Jellis C.L., Jenkins C., Coombes J.S., Marwick TH.Association of cardiac autonomic neuropathy with subclinical myocardialdysfunction in type 2 diabetes. // JACC Cardiovasc Imaging. –2010. –vol.
3(12).– p. 1207–15.155-Sakata S., Lebeche D., Sakata Y., Sakata N., Chemaly E.R., Liang L.,Nakajima-Takenaka C., Tsuji T., Konishi N., del Monte F., Hajjar RJ., TakakiM. Transcoronary gene transfer of SERCA2a increases coronary blood flow anddecreases cardiomyocyte size in a type 2 diabetic rat model. // Am J PhysiolHeart Circ Physiol. –2007. –vol. 292. – p. H1204–H1207.156-Santilli F., Formoso G., Sbraccia P., Averna M., Miccoli R., Di Fulvio P.,et al. Postprandial hyperglycemia is a determinant of platelet activation in earlytype 2 diabetes mellitus. // J Thromb Haemost.
–2010. – vol. 8. – p. 828 – 837.157-Schalkwijk C.G., Baidoshvili A., Stehouwer C.D., van Hinsbergh V.W.,Niessen H.W. Increased accumulation of the glycoxidation product Nepsilon(carboxymethyl)lysine in hearts of diabetic patients: generation andcharacterisation of a monoclonal anti-CML antibody. // Biochim Biophys Acta.–2004. –vol. 1636(2-3). – p. 82–89.158-Schannwell C.M., Schneppenheim M., Perings S., Plehn G., Stauer B.E.Left ventricular diastolic dysfunction as an early manifestation of diabeticcardiomyopathy. // Cardiology. –2002. –vol.
98(1-2). – p. 33–39.159-Schillaci G., Pucci G. The importance of instability and visit-to-visitvariability of blood pressure. // Expert Rev. Cardiovasc. Ther. –2010. –vol. 8(8).– p. 1095–1097.129160-Schrier, R. W. Renal volume, renin-angiotensin-aldosterone system,hypertension, and left ventricular hypertrophy in patients with autosomaldominant polycystic kidney disease. // J. Am. Soc. Nephrol. –2009. –vol. 20(9).– p. 1888–1893.161-Shah A.M., Uno H., Køber L., Velazquez E.J., Maggioni A.P.,MacDonald M.R., Petrie M.C., McMurray J.J., Califf R.M., Pfeffer M.A.,Solomon S.D. The inter-relationship of diabetes and left ventricular systolicfunction on outcome after high-risk myocardial infarction. // Eur J Heart Fail.
–2010. –vol. 12(11). – p. 1229–1237.162-Sherif F. Nagueh., Otto A. Smiseth., Christopher P. Appleton. et al.Recommendations for the Evaluation of Left Ventricular Diastolic Function byEchocardiography: An Update from the American Society of Echocardiographyand the European Association of Cardiovascular Imaging. // J Am SocEchocardiogr. –2016.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
